{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:55:19Z","timestamp":1790999719716,"version":"4.1.0"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7961-26","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:11:46Z","timestamp":1790633506000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer in a Patient with Combined Pulmonary Fibrosis and Emphysema: A Case Report"],"prefix":"10.2169","author":[{"given":"Yuki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Okuzumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kitasato University Kitasato Institute Hospital, Japan"},{"name":"Department of Radiation Oncology, Juntendo University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayuri","family":"Iwasawa","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yanaihara","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Borghetti P, D\u2019Angelillo R, Facheris G, et al. Recommendations for radiotherapy in patients with lung cancer and interstitial lung disease: a Delphi consensus process of the Italian association of radiotherapy and clinical oncology (AIRO). Lung Cancer 210: 108807, 2025.","DOI":"10.2139\/ssrn.5239531"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Drakopanagiotakis F, Krauss E, Michailidou I, et al. Lung cancer and interstitial lung diseases. Cancers (Basel) 16, 2024.","DOI":"10.20944\/preprints202405.1111.v1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hagiwara Y, Nakayama Y, Kudo S, et al. Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease. J Radiat Res 61: 563-574, 2020.","DOI":"10.1093\/jrr\/rraa018"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cottin V, Selman M, Inoue Y, et al. Syndrome of combined pulmonary fibrosis and emphysema: an official ATS\/ERS\/JRS\/ALAT research statement. Am J Respir Crit Care Med 206: e7-e41, 2022.","DOI":"10.1164\/rccm.202206-1041ST"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Saha A, Dickinson P, Shrimali RK, Salem A, Agarwal S. Is thoracic radiotherapy an absolute contraindication for treatment of lung cancer patients with interstitial lung disease? A systematic review. Clin Oncol (R Coll Radiol) 34: e493-e504, 2022.","DOI":"10.1016\/j.clon.2022.01.043"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nasim F, Moua T. Lung cancer in combined pulmonary fibrosis and emphysema: a large retrospective cohort analysis. ERJ Open Res 6, 2020.","DOI":"10.1183\/23120541.00521-2020"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kalemkerian GP, Khurshid H, Ismaila N. Systemic therapy for small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol 43: 101-105, 2025.","DOI":"10.1200\/JCO-24-02245"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 198: e44-e68, 2018.","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Dingemans AC, Fr\u00fch M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol 32: 839-853, 2021.","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"10","unstructured":"10. Society JR. Japanese Statement on Lung Cancer Complicated by Interstitial Pneumonia, Second Revised Edition [Internet]. Available from: https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20250409112444.html."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Castillo R, Pham N, Ansari S, et al. Pre-radiotherapy FDG PET predicts radiation pneumonitis in lung cancer. Radiat Oncol 9: 74, 2014.","DOI":"10.1186\/1748-717X-9-74"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Otani H, Tanaka T, Murata K, et al. Smoking-related interstitial fibrosis combined with pulmonary emphysema: computed tomography-pathologic correlative study using lobectomy specimens. Int J Chron Obstruct Pulmon Dis 11: 1521-1532, 2016.","DOI":"10.2147\/COPD.S107938"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10: 890-895, 1992.","DOI":"10.1200\/JCO.1992.10.6.890"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327: 1618-1624, 1992.","DOI":"10.1056\/NEJM199212033272302"},{"key":"15","unstructured":"15. Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19: 1441-1464, 2021."},{"key":"16","unstructured":"16. Ganti AKP, Loo BW Jr, Badiyan S, et al. NCCN Guidelines<sup>\u24c7<\/sup> Insights: Small cell lung cancer, version 2.2026. J Natl Compr Canc Netw 24, 2026."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. Ann Intern Med 106: 655-662, 1987.","DOI":"10.7326\/0003-4819-106-5-655"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest 156: 150-162, 2019.","DOI":"10.1016\/j.chest.2019.03.033"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Khan MA, Van Dyk J, Yeung IW, Hill RP. Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol 66: 95-102, 2003.","DOI":"10.1016\/S0167-8140(02)00325-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kanaji N, Shimizu J, Sakai K, et al. Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Ther Adv Respir Dis 14: 1753466620963866, 2020.","DOI":"10.1177\/1753466620963866"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tsujino K, Hirota S, Kotani Y, et al. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64: 1100-1105, 2006.","DOI":"10.1016\/j.ijrobp.2005.09.025"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sas-Korczy\u0144ska B, \u0141uczy\u0144ska E, Kamzol W, Soko\u0142owski A. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer: a single-centre retrospective study. Strahlenther Onkol 193: 141-149, 2017.","DOI":"10.1007\/s00066-016-1069-6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Li F, Liu H, Wu H, Liang S, Xu Y. Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy. Radiat Oncol 16: 70, 2021.","DOI":"10.1186\/s13014-021-01798-2"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Li F, Zhou Z, Wu A, et al. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol 13: 82, 2018.","DOI":"10.1186\/s13014-018-1030-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 391: 1313-1327, 2024.","DOI":"10.1056\/NEJMoa2404873"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Daido W, Masuda T, Imano N, et al. Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non-small-cell lung cancer. Cancers (Basel) 14, 2022.","DOI":"10.3390\/cancers14246236"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Ikeda S, Kato T, Kenmotsu H, et al. A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis. J Thorac Oncol 15: 1935-1942, 2020.","DOI":"10.1016\/j.jtho.2020.08.018"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wang Y, Zhang L, Su Z, Lian X. Risk factors of immune checkpoint inhibitor-related cardiotoxicity: a scoping review. Oncologist 30, 2025.","DOI":"10.1093\/oncolo\/oyaf187"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7961-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:30:09Z","timestamp":1790998209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7961-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7961-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7961-26"}}